MetLife Investment Management
IBRX icon

MetLife Investment Management’s ImmunityBio IBRX Stock Holding History

MetLife Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.97M Buy
225,100
+65,443
+41% +$495K 0.01% 1158
2026
Q1 		$1.22M Sell
159,657
-4,608
-3% -$31.5K 0.01% 1306
2025
Q4 		$325K Buy
164,265
+40,785
+33% +$92.4K ﹤0.01% 2014
2025
Q3 		$304K Sell
123,480
-14,784
-11% -$38.1K ﹤0.01% 2081
2025
Q2 		$365K Buy
138,264
+74,106
+116% +$199K ﹤0.01% 1836
2025
Q1 		$193K Sell
64,158
-25,235
-28% -$76.5K ﹤0.01% 2222
2024
Q4 		$229K Buy
89,393
+27,028
+43% +$113K ﹤0.01% 2238
2024
Q3 		$232K Sell
62,365
-19,928
-24% -$92.2K ﹤0.01% 2211
2024
Q2 		$520K Buy
82,293
+13,446
+20% +$88.7K ﹤0.01% 1701
2024
Q1 		$370K Sell
68,847
-1,977
-3% -$8.95K ﹤0.01% 1835
2023
Q4 		$356K Buy
70,824
+12,345
+21% +$38.7K ﹤0.01% 1893
2023
Q3 		$98.8K Hold
58,479
– – ﹤0.01% 2580
2023
Q2 		$163K Buy
58,479
+41,583
+246% +$118K ﹤0.01% 2398
2023
Q1 		$30.8K Sell
16,896
-27,163
-62% -$84.5K ﹤0.01% 2757
2022
Q4 		$223K Hold
44,059
– – ﹤0.01% 2187
2022
Q3 		$219K Buy
44,059
+18,454
+72% +$84.1K ﹤0.01% 2243
2022
Q2 		$95.3K Sell
25,605
-7,653
-23% -$30.7K ﹤0.01% 2729
2022
Q1 		$187K Buy
33,258
+7,377
+29% +$45.3K ﹤0.01% 2385
2021
Q4 		$157K Buy
25,881
+9,230
+55% +$69.3K ﹤0.01% 2203
2021
Q3 		$162K Sell
16,651
-8,431
-34% -$92.8K ﹤0.01% 2213
2021
Q2 		$358K Buy
25,082
+10,931
+77% +$181K ﹤0.01% 1779
2021
Q1 		$336K Hold
14,151
– – ﹤0.01% 1747
2020
Q4 		$189K Hold
14,151
– – ﹤0.01% 2016
2020
Q3 		$98.1K Hold
14,151
– – ﹤0.01% 2218
2020
Q2 		$174K Buy
+14,151
New +$79.9K ﹤0.01% 1986

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MetLife Investment Management's IBRX Position: Q2 2026 in Review

MetLife Investment Management increased its ImmunityBio (IBRX) stake by 41% in Q2 2026, buying an estimated $495K and bringing the position to 225,100 shares worth $1.97M. The position accounts for 0.01% of the portfolio, ranked #1158.

MetLife Investment Management first reported a position in IBRX in Q2 2020 and has held it in 25 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • MetLife Investment Management held 225,100 shares of ImmunityBio worth $1.97M as of Q2 2026.
  • MetLife Investment Management bought 65,443 ImmunityBio shares in Q2 2026, an estimated $495K.
  • ImmunityBio made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1158 holding.
  • MetLife Investment Management first reported a position in ImmunityBio in Q2 2020 and has held it in 25 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.